Additionally, fusion transcripts such as FGFR2-GAB2 and NPC1-MELK have shown potential as diagnostic markers and therapeutic targets in esophageal adenocarcinoma [15]. This evidence concerns the gene GAB2 and esophageal adenocarcinoma.